Stem cell infusions (with or without total body irradiation [TBI]):\r\n* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >=  days after infusion, and no evidence of graft-versus-host disease (GVHD)\r\n* Autologous stem cell infusion including boost infusion: >=  days
Participants must be at least  days after the transplantation or a donor lymphocyte infusion
Donor lymphocyte infusion within  days prior to enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.
Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible
Patients receiving a donor lymphocyte infusion within  weeks of planned T cell infusion
Patients receiving a donor lymphocyte infusion within  weeks of planned T cell infusion
Subjects who developed aGVHD after unplanned donor lymphocyte infusion.
TREATMENT WITH SJCAR: Prior to planned SJCAR infusion, patients with a history of prior allogeneic HCT must be at least  months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the  days prior to planned infusion
Patients receiving prednisone > . mg/kg/day or equivalent at time of enrollment, or who have received anti- thymocyte globulin (ATG) within  days or have received donor lymphocyte infusion (DLI) or Campath within  days of enrollment.
Donor lymphocyte infusion (DLI) within  days prior to enrollment
Subjects must be at least  days from prior stem cell transplant (autologous or allogeneic) or donor lymphocyte infusion (DLI)
Donor lymphocyte infusion administered to treat relapse or loss of donor chimerism
Prior donor lymphocyte infusions (DLIs) are not necessary
Donor lymphocyte infusions (DLI) within  weeks of JCAR administration
Patients who have had donor lymphocyte infusion (DLI) within  weeks prior to registration
Donor lymphocyte infusion within  days prior to enrollment
Subjects must not have received a donor lymphocyte infusion (DLI) within  weeks prior to the first dose of study medication
Has received donor lymphocyte infusion (DLI) product within  weeks of CAR T cell infusion
Patients receiving prednisone > . mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG) within  days or have received donor lymphocyte infusion (DLI) or Campath within  days of enrollment
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Absolute lymphocyte count < /ul or patient has received lymphodepleting chemotherapy administered at least  hours prior to T cell infusion
Patients who have received donor lymphocyte infusion (DLI) within  days of Viralym-A infusion.
Patients receiving prednisone > . mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG), donor lymphocyte infusion (DLI) or Campath within  days of enrollment
Patients who have received donor lymphocyte infusion (DLI) within  days
Patients who have received donor lymphocyte infusion (DLI) within  days
No change in dosing of immunosuppressive agents in the  weeks preceding the naive T-cell depleted donor lymphocyte infusion
A commitment not to electively taper for a minimum of  days, the immunosuppressive medications ongoing at time of naive T-cell depleted donor lymphocyte infusion
Patients developing SR aGvHD after donor lymphocyte infusion (DLI) or after withdrawal of immunosuppression are eligible
Donor lymphocyte infusion within  weeks prior to treatment start if post-transplant
Logistical requirements:\r\n* Space available in infusion room\r\n* Outpatient infusion pump available if continuous infusion required\r\n* Case discussed with infusion room nursing staff
Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion or boost infusion: ? days after infusion and no evidence of graft versus host disease (GVHD)
Autologous stem cell infusion including boost infusion: ? days
Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.
Less than  months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).
Donor lymphocyte infusion (DLI) is considered a reinduction attempt.
At least  weeks (from first dose) elapsed from donor lymphocyte infusion (DLI) without conditioning.
Patients with acute GVHD developing after a donor lymphocyte infusion.
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed >  weeks prior to CTL infusion
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed >  weeks prior to CTL infusion
The patient has, or accepts to have, an acceptable infusion device for infusion of melflufen
Donor lymphocyte infusion (DLI) within  days prior to enrollment
Donor lymphocyte infusion within  days prior to enrollment
Participant with post-transplant exposure to donor lymphocyte infusion (DLI), or T-cell or IL- targeted medication (e.g. anti-thymocyte globulin [ATG], alemtuzumab, basiliximab, denileukin diftitox) within  days prior
Donor lymphocyte infusion within  wks prior to starting dose of AMG .
Donor lymphocyte infusions (DLI) within  months prior to leukapheresis
Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ? days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ? days
Patients may have had prior treatment for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), including lenalidomide; patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least  days between transplant and study entry; patients may also have had donor lymphocyte infusion if there is at least  days between donor lymphocyte infusion and study entry; patients on immunosuppression are also eligible
Subjects who received an unplanned (not part of the original transplant therapy plan) donor lymphocyte infusion.
Allogeneic cellular therapy: Donor lymphocyte infusions (DLI) are prohibited within  weeks prior to leukapheresis
Participant whose GvHD developed after donor lymphocyte infusion
The patient will need to be available for evaluation within  hours of symptoms of GVHD, occurring within  days of the planned donor lymphocyte infusion
No chemotherapy, RT, donor lymphocyte infusion (DLI) or biologic therapy for lymphoma at least  weeks prior to scheduled treatment
Patients who have received donor lymphocyte infusion (DLI) within  days of Viralym-C infusion.
Received donor lymphocyte infusion (DLI) within  days
Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI) within  weeks of Cycle  Day 
Patients may also have had donor lymphocyte infusion if there is at least  days between donor lymphocyte infusion and study entry
Anticipated planned donor lymphocyte infusion in the first  months post-SCT
Patients may have received a prior allogeneic hematopoietic stem cell transplant (alloHSCT) for any indication and from any donor; patients developing cGvHD after donor lymphocyte infusion (DLI) are also eligible
Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within  months of enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy
Donor lymphocyte infusion within  days prior
Patients who have received donor lymphocyte infusion (DLI) within  days
Patients whose GVHD developed after donor lymphocyte infusion (DLI)
Donor lymphocyte infusion in the preceding  days
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within  days of enrollment, including day of enrollment
FOR THE  SUBJECTS ENROLLED IN YEAR : Subjects who have received stem cell boost or delayed donor lymphocyte infusion within  days of enrollment, including day of enrollment
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within  days of enrollment, including day of enrollment
No donor lymphocyte infusion (DLI) prior to day , and no plans for a DLI in the upcoming  days
Patients may have received no more than one donor lymphocyte infusion (DLI), DLI must have been administered >  weeks prior to enrollment on study, and no plans for a DLI in the upcoming  days
Donor lymphocyte infusions (DLI) within  weeks of JCAR administration
At least  weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning.
